CLINICAL_TRIALS
trial_result
· 2021-08-16
Clinical Trial Update: Safety Study of NHL With 90Y-hLL2 IgG [Phase 1, Phase 2]
Summary
A Phase 1/Phase 2 safety study of 90Y-hLL2 IgG in non-Hodgkin lymphoma has completed.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Gilead Sciences | Conditions: NHL, B-cell NHL | Phase 1, Phase 2 | Status: COMPLETED